Related Experiment Video
Updated: Dec 16, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Huairui Yuan1, Ying Han1, Xuege Wang1
1CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Abstract:
The level of SETD2-mediated H3K36me3 is inversely correlated with that of EZH2-catalyzed H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are molecularly intertwined. Here, we report that SETD2 delays prostate cancer (PCa) metastasis via its substrate EZH2. We show that SETD2 methylates EZH2 which promotes EZH2 degradation. SETD2 deficiency induces a Polycomb-repressive chromatin state that enables cells to acquire metastatic traits. Conversely, mice harboring nonmethylated EZH2 mutant or SETD2 mutant defective in binding to EZH2 develop metastatic PCa. Furthermore, we identify that metformin-stimulated AMPK signaling converges at FOXO3 to stimulate SETD2 expression. Together, our results demonstrate that the SETD2-EZH2 axis integrates metabolic and epigenetic signaling to restrict PCa metastasis.
Insights
SETD2 delays prostate cancer (PCa) metastasis by methylating EZH2, promoting its degradation. This SETD2-EZH2 pathway integrates metabolic and epigenetic signals to restrict PCa spread.
Area of Science:
- Epigenetics
- Cancer Biology
- Metabolic Signaling
Background:
- SETD2 and EZH2 catalyze opposing histone marks (H3K36me3 and H3K27me3).
- The molecular interplay between SETD2 and EZH2 in prostate cancer (PCa) metastasis is not well understood.
Purpose of the Study:
- To investigate the role of SETD2 in regulating EZH2 activity and its impact on PCa metastasis.
- To elucidate the mechanism by which SETD2-EZH2 axis influences prostate cancer progression.
Main Methods:
- Assessed SETD2-mediated methylation of EZH2 in prostate cancer cells.
- Utilized mouse models with specific SETD2 and EZH2 mutations.
- Investigated the role of AMPK signaling and FOXO3 in regulating SETD2 expression.
Main Results:
- SETD2 methylates EZH2, leading to its degradation, thereby delaying PCa metastasis.
- SETD2 deficiency promotes a metastatic phenotype by inducing Polycomb-repressive chromatin.
- Mutant EZH2 or SETD2 impaired in EZH2 binding leads to metastatic PCa.
- Metformin-stimulated AMPK signaling upregulates SETD2 expression via FOXO3.
Conclusions:
- The SETD2-EZH2 axis acts as a crucial regulator, restricting prostate cancer metastasis.
- This axis integrates metabolic cues (via AMPK/FOXO3) and epigenetic modifications to control cancer progression.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

